Source: International Congress 2014 – ILDs 5
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
P. Steiropoulos, P. Boglou, P. Ntolios, A. Tzouvelekis, M. Xanthoudaki, M. Kouratzi, A. Koulelidis, E. Nena, M. E. Froudarakis, D. Bouros (Alexandroupolis, Greece). Platelet activation indices in patients with Idiopathic Pulmonary Fibrosis. Eur Respir J 2014; 44: Suppl. 58, 3769

Member's Comments

No comment yet.

Related content which might interest you: Idiopathic pulmonary fibrosis is associated with a preferential alteration of kCO rather than of DLCO Source: International Congress 2014 – ILDs 6 Year: 2014 Pirfenidone in idiopathic pulmonary fibrosis - description of a German cohort Source: International Congress 2014 – ILDs 4 Year: 2014 Predictors of efficacy of pirfenidone in idiopathic pulmonary fibrosis Source: International Congress 2014 – ILDs 4 Year: 2014 Assessment of telomere length in the combined pulmonary fibrosis and emphysema syndrome Source: International Congress 2014 – ILDs: diagnostic and prognostic investigations Year: 2014 Dissecting the role of TRPC6-channels in bleomycin-induced pulmonary fibrosis Source: International Congress 2014 – ILDs 3 Year: 2014 Safety and efficacy of pirfenidone in severe idiopathic pulmonary fibrosis Source: International Congress 2014 – ILDs 3 Year: 2014 Treatment of Idiopathic Pulmonary Fibrosis Source: Guideline 2015 Year: 2015 LATE-BREAKING ABSTRACT: Efficacy of Pirfenidone for Idiopathic Pulmonary Fibrosis (IPF): an Italian real life study Source: International Congress 2014 – IPF and surroundings Year: 2014 Pulmonary distribution and localization of pirfenidone in animal models of IPF by MS/MS Source: International Congress 2014 – ILDs 4 Year: 2014 IPFdatabase – A new tool for a correct application of idiopathic pulmonary fibrosis guidelines Source: International Congress 2014 – ILDs 2 Year: 2014 Reduction in disease progression with nintedanib in the INPULSIS™ trials Source: International Congress 2014 – Clinical trials in IPF Year: 2014 Analysis of candidate genes of phenotypic expression in idiopathic pulmonary fibrosis Source: International Congress 2014 – ILDs 5 Year: 2014 Transient elastography detection of early liver fibrosis in idiopathic pulmonary fibrosis patients Source: International Congress 2014 – ILDs 2 Year: 2014 Pirfenidone therapy for patients with progressive idiopathic pulmonary fibrosis Source: International Congress 2014 – ILDs 3 Year: 2014 Morality predictors in acute exacerbation of idiopathic pulmonary fibrosis Source: International Congress 2014 – ILDs 6 Year: 2014 Parenchymal cell populations involved in the development of fibrosis Source: International Congress 2014 – ILDs 4 Year: 2014 IPF - Idiopathic Pulmonary Fibrosis Source: Breathe, 15 (2) 153; 10.1183/20734735.ELF152 Year: 2019 Surfactant protein B proforms as potential new biomarkers for idiopathic pulmonary fibrosis Source: International Congress 2014 – ILDs 2 Year: 2014 Angiopoietin-2 gene polymorphism as prognostic factor in caucasians with idiopathic pulmonary fibrosis Source: International Congress 2014 – ILDs 1 Year: 2014 6MWT performance by means of Spiropalm in patients affected by fibrotic idiopathic interstitial pneumonias: Preliminary observations Source: International Congress 2014 – ILDs 6 Year: 2014